Ellagic Acid Containing Nanostructured Lipid Carriers for Topical Application: A Preliminary Study

Area of Science:

• Pharmaceutical Sciences
• Nanotechnology
• Dermatology

Background:

• Ellagic acid (EA) is a natural antioxidant with poor water solubility and biopharmaceutical properties, limiting its therapeutic applications.
• Developing effective delivery systems is crucial to overcome EA's limitations for dermal applications.

Purpose of the Study:

• To create and characterize lipid-based nanoparticle formulations for encapsulating ellagic acid (EA).
• To evaluate the impact of different lipid compositions on EA-loaded nanoparticles for dermal delivery.

Main Methods:

• Nanostructured lipid carriers (NLCs) were prepared using tristearin/tricaprylin (NLC-EA1) and tristearin/labrasol (NLC-EA2).
• Characterization included Cryo-TEM, SAXS, size analysis, entrapment efficiency, stability studies, FRAP assay, and cytotoxicity tests on HaCaT cells.

Main Results:

• Both NLC formulations showed high entrapment efficiency for EA without significant changes in nanoparticle size or morphology.
• NLC-EA1 demonstrated superior EA stability (nearly two months) compared to NLC-EA2 (40 days).
• Both formulations retained significant antioxidant activity, with NLC-EA1 exhibiting lower cytotoxicity.

Conclusions:

• Lipid-based nanoparticles effectively encapsulate EA, improving its solubility and stability for dermal delivery.
• NLC-EA1 formulation is a promising candidate for topical applications due to its enhanced stability and reduced cytotoxicity.
• Encapsulation of EA in NLCs preserves its antioxidant properties while mitigating formulation challenges.